Earlier in October, Eli Lilly missed on both the top and bottom lines in its Q3 financial results, but its sales grew 20%, ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

We recently compiled a list of the 10 Best Reddit Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly And Co.

The current rising stars of Eli Lilly's drug lineup are Mounjaro and Zepbound, two GLP-1 drugs that use tirzepatide as their active ingredient. Mounjaro was first approved by the FDA in May 2022 ...